SEC Tracker
Get the app
CDRE · XBRL financial data

Cadre Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CDRE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers125,114124,583*137,860144,309109,408175,984*130,106157,109155,869167,224*155,429207,126
Cost of goods and services sold71,51174,825*80,23285,65969,39298,797*73,97592,86089,24494,601*95,263119,991
Gross profit53,60349,758*57,62858,65040,01677,187*56,13164,24966,62572,623*60,16687,135
Research and development—year only———year only———year only——
Selling, general and administrative36,31434,904*40,71938,57733,98145,046*41,75345,12945,62750,619*48,83363,220
Total operating expenses36,86937,081*45,64938,69734,59047,784*42,57949,56447,95152,183*52,67564,673
Operating income (loss)16,73412,677*11,97919,9535,42629,403*13,55214,68518,67420,440*7,49122,462
Interest expense1,073804*1,6372,0031,9912,191*2,2313,590————
Other income (expense)(315)541*(1,444)(336)1,555(4,496)*1,2876,114(802)856*(389)(529)
Income tax expense (benefit)4,2932,820*1,9705,0471,3359,733*3,3604,9983,9035,926*8565,507
Net income (loss)11,0539,594*6,92812,5673,65512,983*9,24812,21110,94111,739*1,97511,407
Earnings per share, basic USD per share0.290.26*0.180.310.090.32*0.230.300.270.28*0.050.27
Earnings per share, diluted USD per share0.290.25*0.180.310.090.32*0.230.300.270.23*0.050.26
Weighted average shares, basic thousands of shares37,58637,587*37,94740,60740,60840,608*40,61940,66240,66741,512*42,55842,810
Weighted average shares, diluted thousands of shares37,93138,264*38,55440,85540,94940,956*40,98140,94240,97850,751*43,36443,391

Balance sheet

CSV

Fiscal quarters (CDRE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents69,41287,69187,052105,90392,989124,933133,431137,469150,875122,89841,27253,984
Accounts receivable61,26158,36068,10772,68569,43293,52382,902108,12799,426110,607111,292128,445
Inventory82,54680,97695,75995,63799,58382,35191,786109,604112,201100,263130,989129,120
Total current assets236,722245,843269,328294,990285,912327,571332,515381,016386,216365,866318,764348,117
Property and equipment, net43,65744,64746,70946,71846,22145,24345,08081,90977,59078,822124,115125,441
Right-of-use asset6,6436,5549,9879,62416,92215,45415,59521,31421,71919,77822,88525,194
Goodwill81,21281,667148,912148,141148,944148,157148,611174,462179,169181,406231,225233,907
Total assets420,505431,179599,442620,632616,615652,713656,293794,437792,055770,031879,736917,298
Accounts payable30,73328,41830,28231,48927,56529,64432,12232,00426,99722,32539,90138,895
Accrued liabilities38,67344,52447,46746,64547,24146,41341,60456,53161,36361,06682,38797,346
Current portion of long-term debt13,25112,32015,23413,12813,13411,37511,38016,26516,26616,26616,26320,012
Total current liabilities89,70695,20695,55693,05095,08194,12593,666106,068106,044104,495141,169162,417
Total deposits—9,757———10,002———32,462——
Long-term debt130,309127,812200,601198,233194,949211,830209,134298,885294,971290,987349,567354,319
Lease liability, non-current3,6033,1865,8226,06212,03210,73310,98315,64516,03315,03914,96917,257
Total liabilities230,508234,017328,741321,252316,334341,198338,731461,977451,681452,227543,620570,496
Retained earnings (accumulated deficit)(22,693)(16,106)(12,467)(3,453)(3,351)6,07911,46819,81726,89534,77032,46339,590
Total stockholders' equity189,997197,162270,701299,380300,281311,515317,562332,460340,374317,804336,116346,802
Total liabilities and equity420,505431,179599,442620,632616,615652,713656,293794,437792,055770,031879,736917,298
Common shares outstanding (cover page) thousands of shares37,58637,58740,60640,60840,60840,60840,66040,66440,66442,72742,79742,821

Cash flows

CSV

Fiscal quarters (CDRE's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)11,0539,594*6,92812,5673,65512,983*9,24812,21110,94111,739*1,97511,407
Stock-based compensation2,208*2,308*2,0672,084*2,104*2,114*1,9682,425*2,447*5,399*1,9262,960*
Depreciation and amortization4,165*3,352*3,9424,620*3,763*4,095*3,8564,676*5,376*4,725*5,7286,171*
Net cash from operating activities17,991*26,949*2,13711,143*(5,214)*23,711*17,3912,588*22,476*21,250*22,52122,131*
Purchases of property and equipment1,844*2,479*1,3432,022*1,016*1,287*1,3091,424*849*3,274*2,6803,453*
Net cash from investing activities(1,844)*(2,478)*(142,636)(2,493)*(991)*(1,306)*(1,309)(91,008)*(849)*(3,203)*(156,233)(13,753)*
Proceeds from issuing common stock——73,53518,241*0*0*——————
Dividends paid3,006*3,007*3,2893,553*3,553*3,553*3,8593,862*3,863*3,864*4,2824,280*
Net cash from financing activities(2,277)*(6,538)*139,78610,095*(7,050)*9,836*(7,812)90,755*(7,591)*(43,766)*52,8924,390*
Net change in cash13,630*18,279*(639)18,851*(12,914)*31,944*8,4984,038*13,406*(25,548)*(81,675)14,017*

Compare with peers

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Cadre Holdings53,984207,12622,131*42.8M— 10-QJun 30, 2026
Avanos Medical65,600182,200(12,300)46.8M5.3 quarters 10-QMar 31, 2026
Kestra Medical Technologies68,55830,971(32,295)59.6M4.9 quarters 10-QJul 31, 2026
Beta Bionics81,55135,505(12,287)*54.4M13.0 quarters 10-QSep 30, 2026
Iradimed63,28824,2036,997*12.8M— 10-QSep 30, 2026
Mimedx Group120,79162,2833,919*145.9M— 10-QSep 30, 2026
Embecta214,700271,70041,800*56.7M— 10-QJun 30, 2026
Orthofix Medical103,810210,933(6,224)*40.7M16.7 quarters 10-QJun 30, 2026
Angiodynamics33,97380,915(15,330)42.1M2.2 quarters 10-QAug 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.